Updates on Treatment of Gemcitabine-Refractory Pancreatic Adenocarcinoma

被引：0

作者：

Makrilia, Nektaria ^{[1
]}

Syrigos, Kostas N. ^{[1
]}

Saif, Muhammad W. ^{[2
,3
]}

机构：

[1] Sotiria Gen Hosp, Athens Med School, Dept Med 3, Oncol Unit, Athens, Greece

[2] Columbia Univ Coll Phys & Surg, 177 Ft Washington Ave,Suite 6-435, New York, NY 10032 USA

[3] New York Presbyterian Hosp, Pancreas Ctr, New York, NY USA

来源：

JOURNAL OF THE PANCREAS | 2011年 / 12卷 / 04期

关键词：

capecitabine; lapatinib; Pancreatic Neoplasms; S-1; Treatment Failure;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gemcitabine monotherapy and gemcitabine-based regimens are the current standard of care for locally advanced or metastatic pancreatic adenocarcinoma. However, there is still great controversy over the role of salvage chemotherapy after failure of gemcitabine. This review is an update on the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in the treatment of refractory pancreatic cancer, as they were reported in Abstracts #e14542 and #e14588.

引用

页码：351 / 354

页数：4

共 50 条

[1] Capecitabine is an effective treatment in gemcitabine-refractory advanced pancreatic cancer
Arrazubi, V
Illarramendi, J.
Lainez, N.
Salgado, E.
Martinez, M.
Amillano, K.
Vera, R.
ANNALS OF ONCOLOGY, 2008, 19 : 75 - 75
[2] A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma
Starling, N.
Hawkes, E. A.
Chau, I.
Watkins, D.
Thomas, J.
Webb, J.
Brown, G.
Thomas, K.
Barbachano, Y.
Oates, J.
Cunningham, D.
ANNALS OF ONCOLOGY, 2012, 23 (04) : 942 - 947
[3] Prognostic factors in patients with gemcitabine-refractory pancreatic cancer
Nakachi, Kohei
Furuse, Junji
Ishii, Hiroshi
Suzuki, Ei-ichiro
Yoshino, Masahiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (02) : 114 - 120
[4] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Kulke, Matthew H.
Blaszkowsky, Lawrence S.
Ryan, David P.
Clark, Jeffrey W.
Meyerhardt, Jeffrey A.
Zhu, Andrew X.
Enzinger, Peter C.
Kwak, Eunice L.
Muzikansky, Alona
Lawrence, Colleen
Fuchs, Charles S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
[5] Paclitaxel as a Salvage Chemotherapy in Patients With Gemcitabine-Refractory Pancreatic Cancer
Maeda, S.
Motoi, F.
Kawaguchi, K.
Onogawa, T.
Morikawa, T.
Okaue, A.
Takadate, T.
Rikiyama, T.
Katayose, Y.
Egawa, S.
Unno, M.
PANCREAS, 2009, 38 (08) : 1024 - 1024
[6] Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
Park, Se Jun
Kim, Hyunho
Shin, Kabsoo
Lee, Myung Ah
Hong, Tae Ho
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (11) : 1021 - 1030
[7] Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
Kim, Jung Hoon
Lee, Sang-Cheol
Oh, Sung Yong
Song, Seo-Young
Lee, Namsu
Nam, Eun Mi
Lee, Soonil
Hwang, In Gyu
Lee, Hyo Rak
Lee, Kyu Taek
Bae, Sang-Byung
Kim, Han Jo
Jang, Joung Soon
Lim, Do Hyoung
Lee, Hyun Woo
Kang, Seok Yun
Kang, Jung Hun
CANCER COMMUNICATIONS, 2018, 38
[8] Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Moon Jae Chung
Huapyong Kang
Ho Gak Kim
Jong Jin Hyun
Jun Kyu Lee
Kwang Hyuck Lee
Myung Hwan Noh
Dae Hwan Kang
Sang Hyub Lee
Seungmin Bang
World Journal of Gastrointestinal Oncology, 2018, (12) : 505 - 515
[9] Weekly epirubicin as salvage therapy inpatient with gemcitabine-refractory pancreatic cancer
Cereda, S.
Rognone, A.
Mazza, E.
Fugazza, C.
Ceraulo, D.
Ghidini, M.
Villa, E.
Reni, M.
ANNALS OF ONCOLOGY, 2008, 19 : 73 - 73
[10] Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
Tschoep-Lechner, Katharina Elisabeth
Milani, Valeria
Berger, Frank
Dieterle, Nelli
Abdel-Rahman, Sultan
Salat, Christoph
Issels, Rolf-Dieter
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2013, 29 (01) : 8 - 16

← 1 2 3 4 5 →